👀 Ones to watch: The MOST undervalued shares to buy right nowSee Undervalued Shares

Pfizer rises 1.8% in pre-market after upbeat Q2 earnings

Published 28/07/2015, 09:06 pm
© Reuters.  Pfizer gains after upbeat Q2 earnings
PFE
-
ESZ24
-
1YMZ24
-
NQZ24
-

Investing.com - U.S. pharmaceutical giant Pfizer (NYSE:PFE) reported better-than-expected second quarter earnings ahead of Tuesday’s opening bell, sending its shares higher in pre-market trade.

Pfizer said adjusted earnings per share came in at 56 cents in the three months ended June 30, above expectations for adjusted earnings of 52 cents per share.

The company’s second quarter revenue totaled $11.9 billion, beating forecasts for revenue of $11.42 billion.

Ian Read, Chairman and Chief Executive Officer, stated, "Our second-quarter and year-to-date financial performance is the result of continued business momentum, driven by solid execution of recent product launches in our Innovative Products business."

Pfizer raised midpoint of 2016 revenue by 3 cents due to strong performance to date and an improved business outlook.

Following the release of the report, shares in Pfizer rose 1.77% in pre-market trade to $34.99 compared to Monday's closing price of $34.38.

Meanwhile, U.S. stock futures pointed to a mildly higher open. The Dow futures indicated a gain of 0.45% at the open, the S&P 500 futures pointed to a rise of 0.55%, while Nasdaq 100 futures advanced 0.6%.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.